Global Antibiotics Market - 2023-2030

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,350	195 Pages	DataM Intelligence 4Market Research LLP	July, 2023	DTAM18043745

Best Price Guarantee
Price	from $4,350
Length	195 Pages
Publisher	DataM Intelligence 4Market Research LLP
Published Date	July, 2023
SKU	DTAM18043745

Global Antibiotics Market - 2023-2030

The Global Antibiotics Market reached US$ 40.9 billion in 2022 and is projected to witness lucrative growth by reaching US$ 52.2 billion by 2030. The Global Antibiotics Market is expected to exhibit a CAGR of 3.1% during the forecast period 2023-2030.

The increasing number of infectious disorders, government initiatives, increasing consumptions, research grant endeavors, promising reimbursement guidelines, and market consequences like product takeoffs, product permissions, partnerships, acquisitions, alliances, and expansion, among others are anticipated to boost the Global Antibiotics Market growth in the forecast period. The key market players in the Antibiotics market include GlaxoSmithKline PLC, Johnson & Johnson Inc., Merck & Co. Inc., and Pfizer Inc.

Market Dynamics

The Increasing Prevalence Of Infectious Diseases Drives The Growth Of The Antibiotics Market

The growing burden of infectious diseases globally is expected to boost the global antibiotics market growth in the forecast period. For instance, according to WHO communicable disease statistics 2022, HIV over 1.5 million individuals were recently contaminated with HIV worldwide in 2021. Also, according to the WHO Global Tuberculosis Report 2022, an estimated global total of 10.6 million individuals fell sick with TB in 2021, comparable to 134 cases per 100 000 inhabitants. Out of all TB patients, 6.7% were individuals living with HIV.

Region-wise, South-East Asia had 45% of total cases, Africa had 23% of cases, and the Western Pacific had 18% of the cases, with fewer percentages in the Eastern Mediterranean, around 8.1% of the cases, the Americas about 2.9 of the issues and Europe over 2.2% of the cases.

In 2021, there were an assessed 1.4 million deaths in HIV-negative individuals and around 187 000 in HIV-positive individuals, for an integrated sum of 1.6 million, which was elevated from the most reasonable assessments of 1.5 million in 2020 and 1.4 million in 2019, and around to the level of 2017.

The Increasing Increasing Research Funding is Expected To Present The Global Antibiotics Market With Growth Opportunities

The increasing research funding is presenting the global antibiotics market with lucrative growth opportunities in the future. For instance, in June 2022, The UK government’s Global AMR Innovation Fund (GAMRIF) funded £4.5 million to sustain the Global Antibiotic Research and Development Partnership (GARDP) to design unique therapies for drug-resistant disorders recognized by the World Health Organization as the most significant danger to global health and development.

The Antimicrobial Resistance Is Estimated To Hamper The Global Antibiotics Market During The Forecast Period

The antibiotic resistance and rarer players interested in active research are anticipated to hamper the growth of the antibiotics market over the forecast period. For instance, the 2021 WHO report represented the antibacterial clinical and preclinical pipeline as stationary and distant from satisfying multinational requirements. Since 2017 just 12 antibiotics have been authorized, 10 of which are from the existing categories with specified mechanisms of antimicrobial resistance (AMR).

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations worldwide. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis.

War anywhere applies the bases for outbreaks and epidemics of communicable infections, from cholera in Yemen, to polio in Syria, and measles in Afghanistan. Indeed, both world wars induced a profound gain in TB deaths. Wars guide to circumstances that are the excellent breeding environment for TB, such as food insecurity and overcrowding in inadequately fanned areas.

This is the alarming condition presently encountering multiple individuals in bomb shelters across Ukraine. Wars destroy healthcare infrastructure, crush immunization programs, and restrict access to quality care. This indicates sick individuals frequently have late diagnoses, resulting in more harmful intricacies and a more significant possibility of onward transmission.

Segment Analysis

The Global Antibiotics Market is segmented based on drug class, spectrum, distribution channels, and region.

Owing To The Increasing Positive Research Outcomes The Carbapenem Drug Class Segment Is Estimated To Hold About 28.9% of the Global Market Share By 2030

Owing to the increasing positive research outcomes, the carbapenem drug class segment is estimated to hold 28.9% of the global antibiotic market share in the forecast period. For instance, in April 2022, data from a phase 3 clinical investigation publicized in the New England Journal of Medicine demonstrated that an oral carbapenem antibiotic might be a choice in treating complicated urinary tract infections (cUTIs) induced by multidrug-resistant bacteria.

Geographical Analysis

Asia-Pacific is estimated to hold 27.6% of the Market Share Owing to the Growing Infectious Diseases Prevalence in this Region.

Owing to the increasing prevalence and presence of a majority of key market players in this region the Asia Pacific market is estimated to exhibit a high shareholding 0f 28.7% in 2030. For instance, according to the WHO 2021 report, South-East Asia accounted for 43% of the assessed TB patients worldwide in 2020 over any different WHO region.

India had 26.0% of TB cases globally, China had 8.5% of the TB cases globally, Indonesia had 8.4% of the cases, the Philippines had 6.0% of the cases, Pakistan had 5.8% of the cases, and Bangladesh had 3.6% of the cases, holding in the sense that these nations and territories also had important decreases in the reporting of patients because of the COVID-19 pandemic. Although HIV preponderance is down, the number of individuals living with HIV increased to over 2.2 million in reporting nations and territories in 2021 because of Asia-Pacific’s large population.

Competitive Landscape

The major global players in the antibiotics market include GlaxoSmithKline PLC, Johnson & Johnson Inc., Merck & Co. Inc., Pfizer Inc., Bayer Healthcare AG, Novartis AG, Sanofi SA, Abbott Laboratories, F. Hoffmann-La Roche AG, and Otsuka Pharmaceutical Co. Ltd among others.

Why Purchase the Report?
• To visualize the Global Antibiotics Market segmentation based on drug class, spectrum, distribution channels, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of antibiotics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Antibiotics Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

1. Methodology and Scope: 1.1. Research Methodology; 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary: 3.1. Snippet by Drug Class; 3.2. Snippet by Spectrum; 3.3. Snippet by Distribution Channels; 3.4. Snippet by Region
4. Dynamics: 4.1. Impacting Factors; 4.1.1. Drivers; 4.1.1.1. New Product Developments; 4.1.1.2. Growing Prevalence of Infectious Diseases; 4.1.2. Restraints; 4.1.2.1. Antimicrobial Resistance; 4.1.3. Opportunity; 4.1.3.1. Funding Initiatives; 4.1.4. Impact Analysis
5. Industry Analysis: 5.1. Porter’s 5 Forces Analysis; 5.2. Supply Chain Analysis; 5.3. Pricing Analysis; 5.4. Regulatory Analysis
6. COVID-19 Analysis: 6.1. Analysis of COVID-19; 6.1.1. Scenario Before COVID-19; 6.1.2. Scenario During COVID-19; 6.1.3. Scenario Post COVID-19; 6.2. Pricing Dynamics Amid COVID-19; 6.3. Demand-Supply Spectrum; 6.4. Government Initiatives Related to the Market During the Pandemic; 6.5. Manufacturers Strategic Initiatives; 6.6. Conclusion
7. By Drug Class: 7.1. Introduction; 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class; 7.1.2. Market Attractiveness Index, By Drug Class; 7.2. Cephalosporin *; 7.2.1. Introduction; 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 7.3. Penicillin; 7.4. Fluoroquinolones; 7.5. Carbapenem; 7.6. Macrolides; 7.7. Sulfonamides; 7.8. Aminoglycosides; 7.9. Others
8. By Spectrum: 8.1. Introduction; 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spectrum; 8.1.2. Market Attractiveness Index, By Spectrum; 8.2. Narrow-spectrum Antibiotics *; 8.2.1. Introduction; 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 8.3. Broad-spectrum Antibiotics
9. By Distribution Channels: 9.1. Introduction; 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels; 9.1.2. Market Attractiveness Index, By Distribution Channels; 9.2. Hospital Pharmacy *; 9.2.1. Introduction; 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 9.3. Retail Pharmacy; 9.4. Online Pharmacy
10. By Region: 10.1. Introduction; 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region; 10.1.2. Market Attractiveness Index, By Region; 10.2. North America; 10.2.1. Introduction; 10.2.2. Key Region-Specific Dynamics; 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class; 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spectrum; 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels; 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 10.2.6.1. The U.S.; 10.2.6.2. Canada; 10.2.6.3. Mexico; 10.3. Europe; 10.3.1. Introduction; 10.3.2. Key Region-Specific Dynamics; 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class; 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spectrum; 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels; 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 10.3.6.1. Germany; 10.3.6.2. The U.K.; 10.3.6.3. France; 10.3.6.4. Spain; 10.3.6.5. Italy; 10.3.6.6. Rest of Europe; 10.4. South America; 10.4.1. Introduction; 10.4.2. Key Region-Specific Dynamics; 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class; 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spectrum; 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels; 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 10.4.6.1. Brazil; 10.4.6.2. Argentina; 10.4.6.3. Rest of South America; 10.5. Asia-Pacific; 10.5.1. Introduction; 10.5.2. Key Region-Specific Dynamics; 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class; 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spectrum; 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels; 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 10.5.6.1. China; 10.5.6.2. India; 10.5.6.3. Japan; Australia; 10.5.6.4. Rest of Asia-Pacific; 10.6. Middle East and Africa; 10.6.1. Introduction; 10.6.2. Key Region-Specific Dynamics; 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class; 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Spectrum; 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
11. Competitive Landscape: 11.1. Competitive Scenario; 11.2. Market Positioning/Share Analysis; 11.3. Mergers and Acquisitions Analysis
12. Company Profiles: 12.1. GlaxoSmithKline PLC; 12.1.1. Company Overview; 12.1.2. Product Portfolio and Description; 12.1.3. Financial Overview; 12.1.4. Key Developments; 12.2. Johnson & Johnson Inc.; 12.3. Merck & Co. Inc.; 12.4. Pfizer Inc.; 12.5. Bayer Healthcare AG; 12.6. Novartis AG; 12.7. Sanofi SA; 12.8. Abbott Laboratories; 12.9. F. Hoffmann-La Roche AG; 12.10. Otsuka Pharmaceutical Co. Ltd; LIST NOT EXHAUSTIVE
13. Appendix: 13.1. About Us and Services; 13.2. Contact Us